Oxford Medical Wins $730K NIH Contract to Develop Blood Dx for Cancer Rx Efficacy

Oxford Biomedical Research plans to use the Phase 2 Small Business Innovation Research contract, awarded by the National Institute of Environmental Health Sciences, to develop a blood test that may permit clinicians to monitor the effectiveness of known cancer prevention drugs and lead to the development of new anti-cancer agents.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.